摘要
目的探讨双黄连抗炎的主要活性成分和药理作用机制。方法通过中药系统药理学分析平台(TCMSP)检索“金银花”“黄芩”“连翘”三味药材的化学成分和作用靶点,构建化合物-靶点网络;通过比较毒物基因组学数据库(Comparative Toxi⁃cogenomics Database,CTD)检索炎症相关基因,构建蛋白互作(protein-protein interaction,PPI)网络,进而在DAVID平台进行基因本体(gene ontology,GO)功能富集分析和KEGG通路富集分析,推测双黄连抗炎的作用机制。结果筛选得到与炎症有关的36个化合物和53个潜在靶点,关键靶点为前列腺素G/H合成酶2(Prostaglandin G/H synthase 2,PTGS2)、前列腺素G/H合成酶1(Prostaglandin G/H synthase 1,PTGS1)、诱导型一氧化氮合酶(Nitric oxide synthase,inducible,NOS2)、转录因子p65(Tran⁃scription factor p65,RELA)、外消旋-α丝氨酸/苏氨酸蛋白激酶(RAC-alpha serine/threonine-protein kinase,AKT1)。GO功能富集分析筛选得到GO条目77个,KEGG通路富集筛选得到46条信号通路。结论初步预测了双黄连抗炎的药效成分和药理作用机制,为进一步深入研究其作用机制提供基础。
Objective To study the main active components and pharmacological mechanisms of the anti-inflammatory function of Shuanghuanglian.Methods The chemical constituents and target proteins of"Lonicerae Japonicae Flos","Scutellariae Radix"and"Forsythiae Fructus"were indexed by the traditional Chinese medicine system pharmacology platform(TCMSP)to construct the com⁃pounds-targets network.The genes related to inflammation were screened by the comparative Toxicogenomics Database(CTD)and pro⁃tein and protein interaction(PPI)network was constructed.Then the Gene ontology(GO)and KEGG pathway enrichment analysis was carried out on the DAVID platform to predict the action mechanism related to anti-inflammation of Shuanghuanglian.Results 36 com⁃pounds and 53 potential targets were screened.The key targets were Prostaglandin G/H synthase 2(PTGS2),Prostaglandin G/H syn⁃thase 1(PTGS1),Nitric oxide synthase,inducible(NOS2),Transcription factor p65(RELA),RAC-alpha serine/threonine-protein kinase(AKT1).77 GO items were obtained by GO function enrichment analysis,and 46 signaling pathways were acquired by KEGG pathway enrichment analysis.Conclusion The active ingredients and pharmacological mechanisms of Shuanghuanglian in treatment of inflam⁃mation were preliminarily predicted,which has provided a basis for further in-depth study on the mechanism.
作者
王博
王瑞
郭丽娜
田会东
王单单
吴作敏
裴媛
WANG Bo;WANG Rui;GUO Lina;TIAN Huidong;WANG Dandan;WU Zuomin;PEI Yuan(Department of Pharmacy,Luohe Central Hospital,Luohe,Henan 462000,China)
出处
《安徽医药》
CAS
2021年第3期435-440,I0001,共7页
Anhui Medical and Pharmaceutical Journal
基金
河南省中药制剂现代化技术研发与临床应用工程研究中心(豫发改高技〔2019〕569号)。
关键词
中草药
药理作用
忍冬属
黄芩
连翘属
炎症
双黄连
网络药理学
Drugs,Chinese herbal
Pharmacologic actions
Lonicera
Scutellaria baicalensis
Forsythia
Inflamma⁃tion
Shuanghuanglian
Network pharmacology
